In patients who have been U have Rifapentine Priftin chemotherapy and subject to the approval of the license in the future again, even in patients well Fs chemotherapy. Although MDV3100 is an early stage of clinical development, compared to abiraterone acetate, the available data promising and suggest that this agent also probably have a significant impact on clinical practice n UK Chsten 5 years. MDV3100 is an antagonist of the androgen receptor that no agonistic activity t and prevents the nucleic Re translocation of the androgen receptor and DNA binding. A phase I dose-escalation II, in 140 M Nnern progressive mCRPC showed that MDV3100 was well tolerated up to a dose of 240 mg, given the F Promotion antitumor activity of t. Accordingly MDV3100 at a dose of 160 mg / day in a Phase III trial in M Nnern with mCRPC that have been re-evaluated U treatment with docetaxel. A second Phase III trial in M Nnern have Fs mCRPC progressive chemotherapy is also under way, expected to report in September 2014. It may, however, also Possible challenges in interpreting fi ndings of this study because of the M Possibility of the placebo arm, a change to abiraterone acetate can be obtained in the future. Taken together, these data confirm to the fi ndings of our survey suggest that abiraterone acetate once and can significantly MDV3100 significant impact on clinical practice in Great Britain In the n Chsten 5 years. However, since this probably influences UX of new agents for CRPC in the near future it will be important that oncologists closely with urologists to explore further, the optimal sequencing of all mCRPC treatments for patients. Probably because in addition to efficiency and safety data from ongoing Phase III trials of abiraterone acetate and MDV3100 is the Ausma the use of these agents and their position in the sequencer Age therapies in the future, and also help determine which patients are treated with these agents, and re oivent docetaxel. It is also interesting to note that, when available, these new therapies in oncology clinics dedicated uro, so that responses can be monitored fa k Should be administered can Is pr Precise and sequential Age of these agents may continue to be monitored and optimized. There was a consensus between oncologists British specific endothelin A receptor antagonist, zibotentan, and the fight against the monoclonal antibodies Body vascular endothelial growth factor, bevacizumab, h tte No influence on the management of mCRPC to the future, with recent results of phase III studies identified negative for as a reason for it. In fact, although fi ndings from a phase II study showed that zibotentan is with improved overall survival compared to placebo at M Nnern with mCRPC connected ndings fi from a phase III trial Similar zibotentan showed verses from placebo no significant improvement in the primary Ren endpoint of overall survival in M nnern sumatriptan with mCRPC. Another phase III trial studyhas also recently on the basis of an examination effi ciency of the early independent Ngigen Monitoring Committee has adopted indicated that each was zibotentan unlikely that nnern their prime Ren endpoints effi ciency for M to meet with metastatic CRPC. A third phase III trial of zibotentan in combination with docetaxel in patients, na Fs chemotherapy with mCRPC.